五洲医疗(301234) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥117,355,998.88, a decrease of 2.60% compared to ¥120,483,351.89 in the same period last year[7] - Net profit attributable to shareholders was ¥12,967,646.49, reflecting a 1.44% increase from ¥12,783,160.84 year-on-year[7] - Basic earnings per share decreased by 23.93% to ¥0.1907, down from ¥0.2507 in the same period last year[7] - Total operating revenue for Q1 2023 was CNY 117,355,998.88, a decrease of 1.0% from CNY 120,483,351.89 in the previous year[20] - Net profit for Q1 2023 reached CNY 12,967,646.49, slightly up from CNY 12,783,160.84 in Q1 2022, representing an increase of 1.4%[21] - Earnings per share for Q1 2023 were CNY 0.1907, compared to CNY 0.2507 in the previous year, reflecting a decrease of 24.0%[21] Cash Flow and Liquidity - The net cash flow from operating activities increased by 9.82% to ¥14,944,036.17, up from ¥13,607,532.78 in the previous year[7] - The net cash flow from operating activities for Q1 2023 was ¥14,944,036.17, an increase from ¥13,607,532.78 in Q1 2022, reflecting a positive trend in operational efficiency[24] - The net cash flow from investment activities was ¥148,318,107.39, a substantial improvement compared to a negative cash flow of ¥15,086,289.79 in Q1 2022[24] - The net increase in cash and cash equivalents for the quarter was ¥162,399,940.82, compared to ¥4,558,898.68 in the same period last year, showcasing strong liquidity growth[25] - The ending balance of cash and cash equivalents reached ¥264,687,108.05, up from ¥45,963,670.46 at the end of Q1 2022, reflecting a significant increase in available cash[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥828,025,558.03, a decrease of 1.96% from ¥844,564,374.07 at the end of the previous year[7] - Total liabilities decreased to CNY 91,648,026.33 from CNY 121,154,488.86, indicating a reduction of 24.4%[18] - The company reported a decrease in total liabilities, with a notable reduction in employee compensation liabilities by 43.82% to ¥7,065,802.90, due to the payment of last year's bonuses[11] - The total current assets decreased to ¥496,927,458.81 from ¥530,850,541.28, reflecting a decline of approximately 6.4%[16] - The company held trading financial assets worth ¥80,703,474.12 at the end of the quarter, down from ¥260,657,736.35, representing a decrease of 69.0%[16] Investment and Income - Investment income surged by 828.56% to ¥2,072,546.21, compared to ¥223,200.00 in the previous year, primarily due to increased returns from financial products[12] - Total cash inflow from investment activities amounted to ¥351,356,583.24, significantly higher than ¥223,200.00 in the previous year, indicating robust investment recovery[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,961[14] - The top three shareholders hold significant stakes: Huang Fan at 24.16% (16,429,650 shares), Xiang Bingyi at 20.25% (13,770,000 shares), and Zhang Hongyu at 9.00% (6,120,000 shares)[14] - The top ten shareholders include a mix of natural persons and private enterprises, with significant ownership concentration among the top three shareholders[14] Operational Costs - Total operating costs for Q1 2023 were CNY 104,154,087.68, down 2.0% from CNY 107,201,390.59 in the same period last year[20] - Sales expenses increased by 54.42% to ¥2,469,964.16, attributed to higher travel and commission costs during the reporting period[12] - The cash outflow for purchasing goods and services was ¥97,535,006.44, down from ¥118,795,350.42, indicating improved cost management[24]